ANI Pharmaceuticals (NASDAQ:ANIP) Issues Earnings Results, Beats Expectations By $0.33 EPS

ANI Pharmaceuticals (NASDAQ:ANIP) posted its earnings results on Friday. The specialty pharmaceutical company reported $1.70 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.37 by $0.33, RTT News reports. The company had revenue of $197.12 million for the quarter, compared to analyst estimates of $179.75 million. ANI Pharmaceuticals had a positive return on equity of 15.87% and a negative net margin of 1.28%. The firm’s quarterly revenue was up 43.4% compared to the same quarter last year. During the same quarter in the previous year, the firm earned $0.82 earnings per share. ANI Pharmaceuticals updated its FY 2025 guidance to 6.270-6.620 EPS.

ANI Pharmaceuticals Price Performance

Shares of NASDAQ ANIP opened at $66.28 on Friday. The company has a debt-to-equity ratio of 1.52, a quick ratio of 1.97 and a current ratio of 2.74. The firm has a fifty day moving average of $66.86 and a 200 day moving average of $60.69. The firm has a market cap of $1.44 billion, a PE ratio of -120.51 and a beta of 0.56. ANI Pharmaceuticals has a one year low of $52.50 and a one year high of $77.00.

Insider Buying and Selling at ANI Pharmaceuticals

In related news, SVP Krista Davis sold 1,000 shares of the business’s stock in a transaction that occurred on Friday, February 21st. The stock was sold at an average price of $60.20, for a total transaction of $60,200.00. Following the completion of the sale, the senior vice president now directly owns 68,624 shares in the company, valued at approximately $4,131,164.80. The trade was a 1.44 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, VP Meredith Cook sold 400 shares of the stock in a transaction on Thursday, March 13th. The shares were sold at an average price of $63.33, for a total value of $25,332.00. Following the completion of the transaction, the vice president now directly owns 80,545 shares of the company’s stock, valued at approximately $5,100,914.85. This represents a 0.49 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 3,200 shares of company stock valued at $197,792 over the last ninety days. Corporate insiders own 12.70% of the company’s stock.

Analyst Ratings Changes

A number of research firms recently commented on ANIP. StockNews.com cut shares of ANI Pharmaceuticals from a “hold” rating to a “sell” rating in a research report on Thursday, April 24th. Jefferies Financial Group initiated coverage on ANI Pharmaceuticals in a research note on Friday, March 14th. They set a “buy” rating and a $80.00 target price on the stock. HC Wainwright reiterated a “buy” rating and issued a $94.00 price target on shares of ANI Pharmaceuticals in a research note on Monday, March 17th. Guggenheim restated a “buy” rating and set a $86.00 price target on shares of ANI Pharmaceuticals in a research note on Friday, April 11th. Finally, Truist Financial increased their price objective on shares of ANI Pharmaceuticals from $62.00 to $65.00 and gave the company a “hold” rating in a research report on Monday, April 21st. One investment analyst has rated the stock with a sell rating, one has assigned a hold rating, seven have given a buy rating and one has given a strong buy rating to the stock. Based on data from MarketBeat, ANI Pharmaceuticals presently has an average rating of “Moderate Buy” and a consensus price target of $80.13.

About ANI Pharmaceuticals

ANI Pharmaceuticals, Inc, a biopharmaceutical company, develops, manufactures, and markets branded and generic prescription pharmaceuticals in the United States and Canada. The company manufactures oral solid dose products; semi-solids, liquids, and topicals; controlled substances; and potent products, as well as performs contract development and manufacturing of pharmaceutical products.